Expertise in
24
conditions

Dr. Santosh Kesari

Neurology
2121 Santa Monica Boulevard, 
Santa Monica, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
24
conditions
2121 Santa Monica Boulevard, 
Santa Monica, CA 

Overview

Santosh Kesari is a Neurologist practicing medicine in Santa Monica, California.

Dr. Kesari is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 312 peer reviewed articles and participating in 20 clinical trials. Dr. Kesari is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

2121 Santa Monica Boulevard, Santa Monica, CA 90404

Additional Areas of Focus

Dr. Kesari has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Procedure, Device, Biological
Study Phase: Phase 2
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 26, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: August 12, 2025
Intervention Type: Drug
Study Drugs: OKN-007, Temozolomide (TMZ)
Study Phase: Phase 2
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Biological
Study Drug: TAEK-VAC-HerBy
Study Phase: Phase 1
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 2
An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
Enrollment Status: Completed
Publish Date: May 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
Enrollment Status: Completed
Publish Date: November 08, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Nivolumab, Ipilimumab, Bevacizumab, Metronomic Temozolomide, 5-day Temozolomide, Lomustine
Study Phase: Phase 1
View 8 Less Clinical Trials

312 Total Publications

Monitoring the Response of a Pineal Parenchymal Tumor of Intermediate Differentiation With Cerebrospinal Fluid Dissemination Using a Circulating Tumor Cell Assay.
Monitoring the Response of a Pineal Parenchymal Tumor of Intermediate Differentiation With Cerebrospinal Fluid Dissemination Using a Circulating Tumor Cell Assay.
Journal: Cureus
Published: February 20, 2026
Similar Doctors
Expertise in
21
conditions
Dr. Timothy Cloughesy
Neurology
Expertise in
21
conditions
Dr. Timothy Cloughesy
Neurology

UCLA Health Bowyer Oncology Center

200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
 (2.9 miles away)
310-206-6909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Cloughesy is a Neurologist practicing medicine in Los Angeles, California. Dr. Cloughesy is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
51
conditions
Dr. Susan Perlman
Neurology
Expertise in
51
conditions
Dr. Susan Perlman
Neurology

Office

300 Medical Plz, 
Los Angeles, CA 
 (2.5 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Perlman is a Neurologist practicing medicine in Los Angeles, California. Dr. Perlman is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

Expertise in
47
conditions
Dr. Perry Shieh
Neurology
Expertise in
47
conditions
Dr. Perry Shieh
Neurology

Office

300 Medical Plz Ste B-200, 
Los Angeles, CA 
 (2.9 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Perry Shieh, MD is a Neurology Specialist in Los Angeles, CA and has over 22 years of experience in the medical field. He graduated from Johns Hopkins University School Of Medicine in 2000. He is affiliated with medical facilities Ronald Reagan UCLA Medical Center and Casa Colina Hospital. Dr. Shieh is highly rated in 47 conditions, according to our data. His clinical expertise encompasses Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Becker Muscular Dystrophy, and Congenital Fiber-Type Disproportion. Dr. Shieh is board certified in Neuromuscular Medicine, American Board Of Psychiatry And Neurology, 2008, Clinical Neurophysiology, American Board Of Psychiatry And Neurology, 2007, and Neurology, American Board Of Psychiatry And Neurology, 2006.

Frequently Asked Questions about Dr. Santosh Kesari

How do I make an appointment with Dr. Santosh Kesari?

You can book an appointment with Dr. Santosh Kesari by calling their office at 310-829-5511. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Santosh Kesari a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Santosh Kesari is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Santosh Kesari specialize in?

While Dr. Santosh Kesari is a Neurology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Santosh Kesari participate in research or clinical trials?

Yes. Dr. Santosh Kesari has published 312 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Santosh Kesari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Santosh Kesari accept my insurance?

Dr. Santosh Kesari accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-829-5511 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kesari's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 8 Advanced Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile